Capital Fund Management S.A. Grows Holdings in Neurocrine Biosciences, Inc. $NBIX

Capital Fund Management S.A. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 203,628 shares of the company’s stock after acquiring an additional 27,987 shares during the quarter. Capital Fund Management S.A. owned 0.21% of Neurocrine Biosciences worth $25,594,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of NBIX. Geneos Wealth Management Inc. raised its holdings in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the period. WPG Advisers LLC purchased a new stake in shares of Neurocrine Biosciences in the first quarter valued at approximately $32,000. SVB Wealth LLC purchased a new stake in shares of Neurocrine Biosciences in the first quarter valued at approximately $35,000. MAI Capital Management raised its stake in shares of Neurocrine Biosciences by 101.2% during the 2nd quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after buying an additional 165 shares during the period. Finally, True Wealth Design LLC lifted its position in shares of Neurocrine Biosciences by 1,215.4% during the 2nd quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after buying an additional 316 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Up 5.6%

Shares of NASDAQ NBIX opened at $151.58 on Friday. The firm has a 50-day simple moving average of $142.73 and a 200-day simple moving average of $134.59. The stock has a market capitalization of $15.11 billion, a price-to-earnings ratio of 36.26, a price-to-earnings-growth ratio of 0.94 and a beta of 0.22. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $157.67.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.59. The company had revenue of $794.90 million during the quarter, compared to analysts’ expectations of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. Neurocrine Biosciences’s revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.81 EPS. As a group, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Insider Activity

In other Neurocrine Biosciences news, CEO Kyle Gano sold 300 shares of the company’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at $19,933,581.79. This represents a 0.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William H. Rastetter sold 18,000 shares of the firm’s stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the sale, the director directly owned 40,360 shares of the company’s stock, valued at $6,127,455.20. This trade represents a 30.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 33,300 shares of company stock worth $4,925,901 over the last ninety days. Corporate insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NBIX shares. Wedbush reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. Zacks Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Finally, Royal Bank Of Canada lifted their price objective on Neurocrine Biosciences from $156.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.53.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.